{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T19:11:43Z","timestamp":1772910703591,"version":"3.50.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,15]]},"DOI":"10.2146\/ajhp170266","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T20:50:16Z","timestamp":1519246216000},"page":"515-522","source":"Crossref","is-referenced-by-count":7,"title":["Alectinib for advanced<i>ALK<\/i>-positive non-small-cell lung cancer"],"prefix":"10.1093","volume":"75","author":[{"given":"Ashley C.","family":"Ly","sequence":"first","affiliation":[{"name":"Wingate University School of Pharmacy, Wingate, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline L.","family":"Olin","sequence":"additional","affiliation":[{"name":"Wingate University School of Pharmacy, Wingate, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan B.","family":"Smith","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041105242427000_b1-0750515","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"Cancer J Clin"},{"key":"key\n\t\t\t\t2019041105242427000_b2-0750515","article-title":"NCCN clinical practice guidelines in oncology","volume-title":"Non-small cell lung cancer","author":"National Comprehensive Cancer Network","year":"2018"},{"key":"key\n\t\t\t\t2019041105242427000_b3-0750515","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041105242427000_b4-0750515","volume-title":"Alecensa (alectinib) package insert","year":"2017"},{"key":"key\n\t\t\t\t2019041105242427000_b5-0750515","volume-title":"Alunbrig (brigatinib) package insert","year":"2017"},{"key":"key\n\t\t\t\t2019041105242427000_b6-0750515","volume-title":"Zykadia (ceritinib) package insert","year":"2017"},{"key":"key\n\t\t\t\t2019041105242427000_b7-0750515","volume-title":"Xalkori (crizotinib) package insert","year":"2017"},{"key":"key\n\t\t\t\t2019041105242427000_b8-0750515","volume-title":"Red Book Online [online database]"},{"key":"key\n\t\t\t\t2019041105242427000_b9-0750515","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105242427000_b10-0750515","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041105242427000_b11-0750515","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"key":"key\n\t\t\t\t2019041105242427000_b12-0750515","doi-asserted-by":"crossref","first-page":"a001115","DOI":"10.1101\/mcs.a001115","article-title":"ALK: a tyrosine kinase target for cancer therapy","volume":"3","author":"Holla","year":"2017","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"key\n\t\t\t\t2019041105242427000_b13-0750515","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00280-014-2578-6","article-title":"Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases","volume":"74","author":"Kodama","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t2019041105242427000_b14-0750515","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"key\n\t\t\t\t2019041105242427000_b15-0750515","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019041105242427000_b16-0750515","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2183\/pjab.91.193","article-title":"The EML4-ALK oncogene: targeting an essential growth driver in human cancer","volume":"91","author":"Mano","year":"2015","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"key\n\t\t\t\t2019041105242427000_b17-0750515","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/1758834015617355","article-title":"ALK inhibitors in non-small cell lung cancer: the latest evidence and developments","volume":"8","author":"Sullivan","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"key\n\t\t\t\t2019041105242427000_b18-0750515","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019041105242427000_b19-0750515","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/00498254.2016.1179821","article-title":"Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects","volume":"47","author":"Morcos","year":"2017","journal-title":"Xenobiotica"},{"key":"key\n\t\t\t\t2019041105242427000_b20-0750515","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/cpdd.298","article-title":"Clinical drug\u2013drug interactions through cytochrome P450 3A (CYP3A) for the selective ALK inhibitor alectinib","volume":"6","author":"Morcos","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"key\n\t\t\t\t2019041105242427000_b21-0750515","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/cpdd.296","article-title":"Effect of food and esomeprazole on the pharmacokinetics of alectinib, a highly selective ALK inhibitor, in healthy subjects","volume":"6","author":"Morcos","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"key\n\t\t\t\t2019041105242427000_b22-0750515","article-title":"Effect of hepatic impairment on the pharmacokinetics of alectinib","author":"ClinicalTrials.gov"},{"key":"key\n\t\t\t\t2019041105242427000_b23-0750515","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019041105242427000_b24-0750515","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","article-title":"Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study","volume":"34","author":"Ou","year":"2015","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041105242427000_b25-0750515","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2016.68.4639","article-title":"Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer","volume":"34","author":"Gadgeel","year":"2016","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041105242427000_b26-0750515","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jtho.2017.02.012","article-title":"Alectinib for patients with ALK rearrangement\u2013positive non\u2013small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401)","volume":"12","author":"Iwama","year":"2017","journal-title":"J Thorac Oncol"},{"key":"key\n\t\t\t\t2019041105242427000_b27-0750515","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4993\/acrt.24.47","article-title":"Successful alectinib treatment for a mechanically ventilated patient with ALK-positive non-small cell lung cancer","volume":"24","author":"Watanabe","year":"2016","journal-title":"Ann Cancer Res Ther"},{"key":"key\n\t\t\t\t2019041105242427000_b28-0750515","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rear-ranged non\u2013small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041105242427000_b29-0750515","first-page":"120ra117","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayma","year":"2012","journal-title":"Sci Transl Med"},{"key":"key\n\t\t\t\t2019041105242427000_b30-0750515","doi-asserted-by":"crossref","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-10-2956","article-title":"The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers","volume":"70","author":"Sasaki","year":"2010","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t2019041105242427000_b31-0750515","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","article-title":"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors","volume":"71","author":"Sasaki","year":"2011","journal-title":"Cancer Res"},{"issue":"suppl","key":"key\n\t\t\t\t2019041105242427000_b32-0750515","article-title":"Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non-small-cell lung cancer (NSCLC)","volume":"34","author":"Puig","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"key\n\t\t\t\t2019041105242427000_b33-0750515","article-title":"Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer","volume":"34","author":"McCoach","year":"2016","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041105242427000_b34-0750515","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-14-1511","article-title":"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib","volume":"20","author":"Katayama","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041105242427000_b35-0750515","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.18632\/oncotarget.2055","article-title":"Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells","volume":"5","author":"Tanimoto","year":"2014","journal-title":"Oncotarget"},{"key":"key\n\t\t\t\t2019041105242427000_b36-0750515","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non\u2013small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov"},{"key":"key\n\t\t\t\t2019041105242427000_b37-0750515","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nm.3667","article-title":"Rationale for co-targeting IGF-1R and ALK in ALK fusion\u2013positive lung cancer","volume":"20","author":"Lovly","year":"2014","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019041105242427000_b38-0750515","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/0008-5472.CAN-15-1010","article-title":"Non\u2013small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases","volume":"76","author":"Isozaki","year":"2016","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t2019041105242427000_b39-0750515","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomized phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041105242427000_b40-0750515","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non\u2013small cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105242427000_b41-0750515","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1200\/JCO.2016.69.9587","article-title":"Improving treatment options for brain metastases from ALK-positive non-small-cell lung cancer","volume":"34","author":"Zabi","year":"2016","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041105242427000_b42-0750515","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.radonc.2011.01.011","article-title":"Dose\u2013effect relation in stereotactic radiotherapy for brain metastases: a systematic review","volume":"98","author":"Wiggenraad","year":"2011","journal-title":"Radiother Oncol"},{"key":"key\n\t\t\t\t2019041105242427000_b43-0750515","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/13696998.2017.1302453","article-title":"The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib","volume":"20","author":"Carlson","year":"2017","journal-title":"J Med Econ"},{"key":"key\n\t\t\t\t2019041105242427000_b44-0750515","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jtho.2016.07.022","article-title":"Sequential therapy with crizotinib and alectinib in ALK-rearranged non\u2013 small cell lung cancer\u2014a multicenter retrospective study","volume":"12","author":"Ito","year":"2017","journal-title":"J Thorac Oncol"},{"key":"key\n\t\t\t\t2019041105242427000_b45-0750515","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.currproblcancer.2016.12.002","article-title":"Targeting the PD-1\/PD-L1 axis in non-small cell lung cancer","volume":"41","author":"Kumar","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"key\n\t\t\t\t2019041105242427000_b46-0750515","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bjc.2014.555","article-title":"PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients","volume":"112","author":"D\u2019Incecco","year":"2015","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t2019041105242427000_b47-0750515","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","article-title":"Induction of PD-L1 expression by the EML4\u2013ALK oncoprotein and downstream signaling pathways in non\u2013small cell lung cancer","volume":"21","author":"Ota","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041105242427000_b48-0750515","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","article-title":"Molecular pathways: next-generation immunotherapy\u2014inhibiting programmed death-ligand 1 and programmed death-1","volume":"18","author":"Chen","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"key\n\t\t\t\t2019041105242427000_b49-0750515","article-title":"Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro)","volume":"34","author":"Hui","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/75\/8\/515\/28347403\/ajhp0515.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T06:14:23Z","timestamp":1570774463000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/75\/8\/515\/5102332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,15]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,4,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp170266","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4,15]]},"published":{"date-parts":[[2018,4,15]]}}}